Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:
64th Annual Society of Hematology Annual Meeting
New Orleans, LA, USA, December 8-12, 2022
Updated results from the Phase 2 ADVANCE Il clinical trial will be presented in an oral presentation on December 12. In addition, the company will present immunomonitoring data in a separate poster presentation on December 10. Members of Mendus’ leadership team, Business Development and R&D will be at the ASH Annual Meeting.
JP Morgan Healthcare Conference Week
San Francisco, CA, USA, January 9-12, 2023
Members of Mendus’ leadership team and Business Development team will be in San Francisco during the JPM Annual Healthcare Meeting 2023.
Redeye Fight Cancer Day 2023
Virtual, January 19, 2023
Erik Manting, CEO of Mendus, will give a presentation and update on Mendus followed by a Q&A session.
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Executive Officer
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
Telephone: +49 160 9352 9951
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/